Symbols / KALA $0.17 -0.81% KALA BIO, Inc.
KALA Chart
About
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 156.48M |
| Enterprise Value | 10.27M | Income | -35.84M | Sales | — |
| Book/sh | -1.17 | Cash/sh | 2.57 | Dividend Yield | — |
| Payout | 0.00% | Employees | 38 | IPO | — |
| P/E | — | Forward P/E | -0.03 | PEG | — |
| P/S | — | P/B | -0.15 | P/C | — |
| EV/EBITDA | -0.25 | EV/Sales | — | Quick Ratio | 0.65 |
| Current Ratio | 0.74 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.64 | EPS next Y | -6.67 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-19 07:00 | ROA | -65.81% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 911.33M |
| Shs Float | 7.66M | Short Float | 0.75% | Short Ratio | 0.40 |
| Short Interest | — | 52W High | 20.60 | 52W Low | 0.16 |
| Beta | -2.37 | Avg Volume | 7.11M | Volume | 2.47M |
| Target Price | — | Recom | None | Prev Close | $0.17 |
| Price | $0.17 | Change | -0.81% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-29 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-09-17 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-09-11 | main | Oppenheimer | Outperform → Outperform | $33 |
| 2025-09-08 | init | Mizuho | — → Outperform | $30 |
| 2025-05-23 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-02-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-19 | reit | Oppenheimer | Outperform → Outperform | $15 |
| 2024-05-17 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-04-01 | reit | Oppenheimer | Outperform → Outperform | $15 |
| 2023-11-17 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2023-05-10 | reit | HC Wainwright & Co. | — → Buy | $24 |
| 2023-05-01 | reit | HC Wainwright & Co. | — → Buy | $22 |
| 2023-04-12 | main | HC Wainwright & Co. | — → Buy | $22 |
| 2023-03-27 | reit | HC Wainwright & Co. | — → Buy | $20 |
| 2023-03-06 | main | HC Wainwright & Co. | — → Buy | $20 |
- Kala Bio Delays 2025 Annual Report Filing - TipRanks Wed, 01 Apr 2026 02
- Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan ue, 31 Mar 2026 20
- EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch - Benzinga Mon, 30 Mar 2026 12
- Why Did KALA Stock Surge 25% Today? - Stocktwits Wed, 11 Mar 2026 07
- KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update - marketbeat.com Sat, 14 Mar 2026 07
- KALA BIO Inc expected to post a loss of $1.44 a share - Earnings Preview - TradingView Fri, 27 Mar 2026 13
- $180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan Wed, 11 Mar 2026 07
- Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent - marketscreener.com Mon, 30 Mar 2026 14
- Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - TMX Newsfile Wed, 18 Mar 2026 07
- Kala Bio rises on plans to leverage AI (KALA:NASDAQ) - Seeking Alpha Wed, 04 Mar 2026 08
- KALA BIO (KALA) Stock Jumps 70% After Pivoting to AI With ‘Palantir for Biotech’ Vision - MEXC Wed, 11 Mar 2026 07
- KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts - marketbeat.com Fri, 27 Mar 2026 08
- Kala says its private AI research agent is now live for biotech clients - Stock Titan Mon, 30 Mar 2026 12
- KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’ - TipRanks Wed, 11 Mar 2026 07
- Why Is Kala Bio Stock Soaring Wednesday? - Kala Bio (NASDAQ:KALA) - Benzinga Wed, 11 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
3.89
-65.37%
|
11.24
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
3.89
-65.37%
|
11.24
|
| Cost Of Revenue |
|
—
|
0.00
-100.00%
|
2.56
-37.52%
|
4.10
|
| Reconciled Cost Of Revenue |
|
—
|
0.00
-100.00%
|
2.56
-37.52%
|
4.10
|
| Gross Profit |
|
—
|
0.00
-100.00%
|
1.33
-81.35%
|
7.14
|
| Operating Expense |
|
34.23
-0.27%
|
34.33
-58.48%
|
82.69
-29.07%
|
116.58
|
| Research And Development |
|
22.09
+18.87%
|
18.59
+5.29%
|
17.65
+53.30%
|
11.52
|
| Selling General And Administration |
|
18.34
-10.83%
|
20.57
-68.38%
|
65.03
-38.10%
|
105.06
|
| General And Administrative Expense |
|
18.34
-10.83%
|
20.57
-68.38%
|
65.03
-38.10%
|
105.06
|
| Other Gand A |
|
18.34
-10.83%
|
20.57
-68.38%
|
65.03
-38.10%
|
105.06
|
| Other Operating Expenses |
|
-6.20
-28.48%
|
-4.83
|
—
|
—
|
| Total Expenses |
|
34.23
-0.27%
|
34.33
-59.73%
|
85.25
-29.36%
|
120.67
|
| Operating Income |
|
-34.23
+0.27%
|
-34.33
+57.81%
|
-81.36
+25.66%
|
-109.43
|
| Total Operating Income As Reported |
|
-40.98
-3.33%
|
-39.66
+51.46%
|
-81.71
+37.27%
|
-130.25
|
| EBITDA |
|
-32.47
+10.01%
|
-36.08
+2.53%
|
-37.02
+72.22%
|
-133.25
|
| Normalized EBITDA |
|
-31.92
+10.27%
|
-35.57
+56.13%
|
-81.08
+24.25%
|
-107.04
|
| Reconciled Depreciation |
|
0.26
-14.52%
|
0.30
-43.58%
|
0.54
-44.92%
|
0.97
|
| EBIT |
|
-32.73
+10.05%
|
-36.38
+3.12%
|
-37.56
+72.02%
|
-134.22
|
| Total Unusual Items |
|
-0.55
-7.65%
|
-0.51
-101.16%
|
44.06
+268.13%
|
-26.21
|
| Total Unusual Items Excluding Goodwill |
|
-0.55
-7.65%
|
-0.51
-101.16%
|
44.06
+268.13%
|
-26.21
|
| Special Income Charges |
|
-0.55
-7.65%
|
-0.51
-101.16%
|
44.06
+268.13%
|
-26.21
|
| Other Special Charges |
|
—
|
—
|
2.58
-91.93%
|
32.01
|
| Restructuring And Mergern Acquisition |
|
0.55
+7.65%
|
0.51
+45.71%
|
0.35
+106.03%
|
-5.80
|
| Net Income |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Pretax Income |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Net Non Operating Interest Income Expense |
|
-3.73
-20.11%
|
-3.10
+53.00%
|
-6.60
+20.23%
|
-8.28
|
| Interest Expense Non Operating |
|
5.78
-0.53%
|
5.81
-19.98%
|
7.27
-13.29%
|
8.38
|
| Net Interest Income |
|
-3.73
-20.11%
|
-3.10
+53.00%
|
-6.60
+20.23%
|
-8.28
|
| Interest Expense |
|
5.78
-0.53%
|
5.81
-19.98%
|
7.27
-13.29%
|
8.38
|
| Interest Income Non Operating |
|
2.06
-24.16%
|
2.71
+308.28%
|
0.66
+538.46%
|
0.10
|
| Interest Income |
|
2.06
-24.16%
|
2.71
+308.28%
|
0.66
+538.46%
|
0.10
|
| Other Income Expense |
|
-0.55
+88.49%
|
-4.77
-111.05%
|
43.14
+273.26%
|
-24.90
|
| Other Non Operating Income Expenses |
|
—
|
-4.26
-359.83%
|
-0.93
-170.63%
|
1.31
|
| Gain On Sale Of Business |
|
—
|
0.00
-100.00%
|
46.99
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Net Income From Continuing Operation Net Minority Interest |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Net Income From Continuing And Discontinued Operation |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Net Income Continuous Operations |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Normalized Income |
|
-37.96
+8.94%
|
-41.69
+53.10%
|
-88.88
+23.64%
|
-116.40
|
| Net Income Common Stockholders |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Diluted EPS |
|
-10.15
+41.50%
|
-17.35
+41.15%
|
-29.48
+72.78%
|
-108.32
|
| Basic EPS |
|
-10.15
+41.50%
|
-17.35
+41.15%
|
-29.48
+72.78%
|
-108.32
|
| Basic Average Shares |
|
3.80
+56.09%
|
2.43
+59.94%
|
1.52
+15.50%
|
1.32
|
| Diluted Average Shares |
|
3.80
+56.09%
|
2.43
+59.94%
|
1.52
+15.50%
|
1.32
|
| Diluted NI Availto Com Stockholders |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
55.48
-0.83%
|
55.95
-35.56%
|
86.82
-37.73%
|
139.43
|
| Current Assets |
|
52.80
-0.14%
|
52.87
-38.48%
|
85.94
-30.90%
|
124.37
|
| Cash Cash Equivalents And Short Term Investments |
|
51.18
+0.56%
|
50.90
-27.80%
|
70.50
-23.49%
|
92.14
|
| Cash And Cash Equivalents |
|
51.18
+0.56%
|
50.90
-27.80%
|
70.50
-23.49%
|
92.14
|
| Other Short Term Investments |
|
—
|
—
|
—
|
0.00
|
| Receivables |
|
—
|
0.24
-96.37%
|
6.50
-62.78%
|
17.45
|
| Accounts Receivable |
|
—
|
0.12
-40.00%
|
0.20
-98.73%
|
15.35
|
| Other Receivables |
|
—
|
0.12
-86.89%
|
0.91
-56.97%
|
2.11
|
| Inventory |
|
—
|
—
|
0.00
-100.00%
|
8.64
|
| Prepaid Assets |
|
—
|
0.56
-20.49%
|
0.70
-68.53%
|
2.22
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
2.04
|
| Assets Held For Sale Current |
|
—
|
0.00
-100.00%
|
7.59
|
0.00
|
| Other Current Assets |
|
1.62
-18.18%
|
1.98
+200.61%
|
0.66
-64.98%
|
1.88
|
| Total Non Current Assets |
|
2.69
-12.76%
|
3.08
+250.68%
|
0.88
-94.17%
|
15.06
|
| Net PPE |
|
2.44
-12.17%
|
2.78
+567.79%
|
0.42
-89.65%
|
4.02
|
| Gross PPE |
|
3.75
-3.45%
|
3.89
+137.07%
|
1.64
-76.17%
|
6.88
|
| Accumulated Depreciation |
|
-1.31
-18.38%
|
-1.11
+9.31%
|
-1.22
+57.22%
|
-2.86
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
1.69
-16.49%
|
2.02
+12556.25%
|
0.02
-98.77%
|
1.30
|
| Machinery Furniture Equipment |
|
0.87
+0.00%
|
0.87
-29.52%
|
1.23
+0.98%
|
1.22
|
| Construction In Progress |
|
0.00
-100.00%
|
0.10
|
0.00
-100.00%
|
1.72
|
| Other Properties |
|
1.19
+33.56%
|
0.89
+128.64%
|
0.39
-85.23%
|
2.65
|
| Leases |
|
—
|
—
|
—
|
0.00
|
| Other Non Current Assets |
|
0.25
-18.27%
|
0.30
-34.85%
|
0.46
-95.82%
|
11.04
|
| Total Liabilities Net Minority Interest |
|
43.15
-10.93%
|
48.45
-28.60%
|
67.85
-44.67%
|
122.62
|
| Current Liabilities |
|
16.96
+103.16%
|
8.35
-67.51%
|
25.68
-31.36%
|
37.42
|
| Payables And Accrued Expenses |
|
3.21
-25.64%
|
4.32
-48.61%
|
8.41
-57.02%
|
19.56
|
| Payables |
|
0.63
-31.66%
|
0.92
-67.55%
|
2.83
-42.19%
|
4.90
|
| Accounts Payable |
|
0.63
-31.66%
|
0.92
-67.55%
|
2.83
-42.19%
|
4.90
|
| Current Accrued Expenses |
|
2.58
-24.02%
|
3.40
-38.99%
|
5.58
-61.97%
|
14.66
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.39
-8.64%
|
2.62
-21.54%
|
3.33
-47.28%
|
6.32
|
| Current Debt And Capital Lease Obligation |
|
10.72
+3108.38%
|
0.33
-93.34%
|
5.01
+605.06%
|
0.71
|
| Current Debt |
|
10.34
|
—
|
5.00
|
—
|
| Other Current Borrowings |
|
10.34
|
—
|
5.00
|
—
|
| Current Capital Lease Obligation |
|
0.38
+13.77%
|
0.33
+2469.23%
|
0.01
-98.17%
|
0.71
|
| Current Deferred Liabilities |
|
0.64
-40.74%
|
1.07
-77.53%
|
4.78
-31.74%
|
7.01
|
| Current Deferred Revenue |
|
0.64
-40.74%
|
1.07
-74.34%
|
4.19
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
4.15
+8.62%
|
3.82
|
| Total Non Current Liabilities Net Minority Interest |
|
26.20
-34.67%
|
40.10
-4.89%
|
42.16
-50.52%
|
85.20
|
| Long Term Debt And Capital Lease Obligation |
|
21.54
-40.16%
|
35.99
-5.13%
|
37.94
-52.27%
|
79.48
|
| Long Term Debt |
|
20.10
-41.21%
|
34.19
-9.88%
|
37.94
-51.94%
|
78.93
|
| Long Term Capital Lease Obligation |
|
1.43
-20.29%
|
1.80
|
0.00
-100.00%
|
0.55
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.88
|
| Other Non Current Liabilities |
|
4.66
+13.36%
|
4.11
-2.70%
|
4.22
-12.75%
|
4.84
|
| Stockholders Equity |
|
12.33
+64.34%
|
7.50
-60.45%
|
18.97
+12.91%
|
16.80
|
| Common Stock Equity |
|
12.33
+64.34%
|
7.50
-60.45%
|
18.97
+12.91%
|
16.80
|
| Capital Stock |
|
0.01
+100.00%
|
0.00
+50.00%
|
0.00
+100.00%
|
0.00
|
| Common Stock |
|
0.01
+100.00%
|
0.00
+50.00%
|
0.00
+100.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
6.09
+120.75%
|
2.76
+61.65%
|
1.71
+30.30%
|
1.31
|
| Ordinary Shares Number |
|
6.09
+120.75%
|
2.76
+61.65%
|
1.71
+30.30%
|
1.31
|
| Additional Paid In Capital |
|
680.25
+6.80%
|
636.91
+5.07%
|
606.18
+8.40%
|
559.19
|
| Retained Earnings |
|
-667.92
-6.12%
|
-629.41
-7.19%
|
-587.21
-8.26%
|
-542.39
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
|
0.00
|
0.00
|
| Total Equity Gross Minority Interest |
|
12.33
+64.34%
|
7.50
-60.45%
|
18.97
+12.91%
|
16.80
|
| Total Capitalization |
|
32.43
-22.21%
|
41.69
-26.74%
|
56.91
-40.55%
|
95.73
|
| Working Capital |
|
35.84
-19.50%
|
44.52
-26.11%
|
60.26
-30.69%
|
86.94
|
| Invested Capital |
|
42.77
+2.58%
|
41.69
-32.65%
|
61.91
-35.33%
|
95.73
|
| Total Debt |
|
32.25
-11.21%
|
36.32
-15.43%
|
42.95
-46.44%
|
80.19
|
| Capital Lease Obligations |
|
1.81
-14.96%
|
2.13
+16307.69%
|
0.01
-98.97%
|
1.26
|
| Net Tangible Assets |
|
12.33
+64.34%
|
7.50
-60.45%
|
18.97
+12.91%
|
16.80
|
| Tangible Book Value |
|
12.33
+64.34%
|
7.50
-60.45%
|
18.97
+12.91%
|
16.80
|
| Current Provisions |
|
—
|
—
|
0.81
-92.17%
|
10.30
|
| Duefrom Related Parties Current |
|
—
|
0.00
-100.00%
|
5.39
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-29.38
-5.21%
|
-27.93
+64.61%
|
-78.91
+27.10%
|
-108.23
|
| Cash Flow From Continuing Operating Activities |
|
-29.38
-5.21%
|
-27.93
+64.61%
|
-78.91
+27.10%
|
-108.23
|
| Net Income From Continuing Operations |
|
-38.51
+8.74%
|
-42.20
+5.85%
|
-44.82
+68.57%
|
-142.60
|
| Depreciation Amortization Depletion |
|
0.26
-14.52%
|
0.30
-43.58%
|
0.54
-44.92%
|
0.97
|
| Depreciation And Amortization |
|
0.26
-14.52%
|
0.30
-43.58%
|
0.54
-44.92%
|
0.97
|
| Other Non Cash Items |
|
2.26
+194.60%
|
-2.39
-204.32%
|
2.29
-89.83%
|
22.53
|
| Stock Based Compensation |
|
8.39
+12.41%
|
7.46
+6.49%
|
7.01
-56.44%
|
16.09
|
| Operating Gains Losses |
|
—
|
—
|
-44.41
-923.21%
|
5.39
|
| Change In Working Capital |
|
-1.78
-120.00%
|
8.89
+1711.61%
|
0.49
+104.63%
|
-10.62
|
| Change In Receivables |
|
—
|
0.08
-99.48%
|
15.14
+363.00%
|
-5.76
|
| Changes In Account Receivables |
|
—
|
0.08
-99.48%
|
15.14
+363.00%
|
-5.76
|
| Change In Inventory |
|
0.00
-100.00%
|
7.54
+341.69%
|
1.71
+127.30%
|
-6.26
|
| Change In Prepaid Assets |
|
0.36
-93.85%
|
5.83
+390.39%
|
-2.01
+29.73%
|
-2.86
|
| Change In Payables And Accrued Expense |
|
-1.82
+57.95%
|
-4.33
+69.10%
|
-14.00
-383.15%
|
4.95
|
| Change In Accrued Expense |
|
-1.53
+36.91%
|
-2.42
+79.69%
|
-11.93
-795.80%
|
1.71
|
| Change In Payable |
|
-0.29
+84.72%
|
-1.90
+8.29%
|
-2.08
-164.25%
|
3.23
|
| Change In Account Payable |
|
-0.29
+84.72%
|
-1.90
+8.29%
|
-2.08
-164.25%
|
3.23
|
| Change In Other Current Assets |
|
0.00
+100.00%
|
-0.14
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
-0.32
-2353.85%
|
-0.01
+96.22%
|
-0.34
+50.07%
|
-0.69
|
| Investing Cash Flow |
|
-0.21
+51.52%
|
-0.43
-100.68%
|
62.72
-11.42%
|
70.80
|
| Cash Flow From Continuing Investing Activities |
|
-0.21
+51.52%
|
-0.43
-100.68%
|
62.72
-11.42%
|
70.80
|
| Net PPE Purchase And Sale |
|
-0.21
+63.06%
|
-0.56
-182.91%
|
-0.20
+74.94%
|
-0.79
|
| Purchase Of PPE |
|
-0.21
+65.90%
|
-0.61
-94.89%
|
-0.31
+64.67%
|
-0.89
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.05
-58.77%
|
0.11
+23.91%
|
0.09
|
| Capital Expenditure |
|
-0.21
+65.90%
|
-0.61
-94.89%
|
-0.31
+94.35%
|
-5.54
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
0.13
+1575.00%
|
0.01
-99.99%
|
76.25
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-9.87
-97.64%
|
-4.99
|
0.00
|
| Sale Of Investment |
|
0.00
-100.00%
|
10.00
+100.00%
|
5.00
-93.44%
|
76.25
|
| Net Business Purchase And Sale |
|
—
|
0.00
-100.00%
|
62.91
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
—
|
-4.65
|
| Gain Loss On Sale Of Business |
|
—
|
0.00
+100.00%
|
-46.99
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-4.65
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-4.65
|
| Financing Cash Flow |
|
29.88
+251.23%
|
8.51
+207.10%
|
-7.94
-118.66%
|
42.55
|
| Cash Flow From Continuing Financing Activities |
|
29.88
+251.23%
|
8.51
+207.10%
|
-7.94
-118.66%
|
42.55
|
| Net Issuance Payments Of Debt |
|
-5.04
+49.55%
|
-10.00
+75.02%
|
-40.04
-15123.95%
|
-0.26
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
77.78
|
| Repayment Of Debt |
|
-5.04
+49.55%
|
-10.00
+75.02%
|
-40.04
+48.70%
|
-78.05
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
77.78
|
| Long Term Debt Payments |
|
-5.04
+49.55%
|
-10.00
+75.02%
|
-40.04
+48.70%
|
-78.05
|
| Net Long Term Debt Issuance |
|
-5.04
+49.55%
|
-10.00
+75.02%
|
-40.04
-15123.95%
|
-0.26
|
| Net Common Stock Issuance |
|
26.43
+42.56%
|
18.54
-41.70%
|
31.80
-22.89%
|
41.23
|
| Proceeds From Stock Option Exercised |
|
0.08
+67.39%
|
0.05
-84.72%
|
0.30
-81.01%
|
1.58
|
| Net Other Financing Charges |
|
-0.12
+94.17%
|
-2.04
|
—
|
—
|
| Changes In Cash |
|
0.29
+101.44%
|
-19.85
+17.75%
|
-24.13
-571.16%
|
5.12
|
| Beginning Cash Position |
|
50.90
-28.06%
|
70.75
-25.44%
|
94.88
+5.71%
|
89.76
|
| End Cash Position |
|
51.18
+0.56%
|
50.90
-28.06%
|
70.75
-25.44%
|
94.88
|
| Free Cash Flow |
|
-29.59
-3.69%
|
-28.54
+63.98%
|
-79.22
+30.37%
|
-113.77
|
| Interest Paid Supplemental Data |
|
4.61
-0.22%
|
4.62
-22.46%
|
5.96
-12.86%
|
6.84
|
| Amortization Of Securities |
|
—
|
—
|
—
|
0.02
|
| Common Stock Issuance |
|
26.43
+42.56%
|
18.54
-41.70%
|
31.80
-22.89%
|
41.23
|
| Issuance Of Capital Stock |
|
34.96
+70.54%
|
20.50
-35.52%
|
31.80
-22.89%
|
41.23
|
| Net Preferred Stock Issuance |
|
8.54
+334.50%
|
1.97
|
0.00
|
—
|
| Preferred Stock Issuance |
|
8.54
+334.50%
|
1.97
|
0.00
|
—
|
| Sale Of Business |
|
—
|
0.00
-100.00%
|
62.91
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-04 View
- 8-K2026-02-20 View
- 8-K2026-02-05 View
- 8-K2026-02-02 View
- 8-K2026-01-23 View
- 8-K2026-01-08 View
- 8-K2026-01-06 View
- 8-K2026-01-02 View
- 8-K2025-12-29 View
- 42025-12-22 View
- 8-K2025-12-16 View
- 8-K2025-12-16 View
- 8-K2025-12-05 View
- 42025-11-26 View
- 8-K2025-11-25 View
- 10-Q2025-11-19 View
- 8-K2025-11-12 View
- 8-K2025-11-10 View
- 42025-10-24 View
- 42025-10-24 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|